US FDA declines to approve Summit lung cancer drug after trial misses key survival goal Reuters
US FDA declines to approve Summit lung cancer drug after trial misses key survival goal - Reuters
In short
Federal regulators reviewed the oncology treatment candidate developed by Summit and chose not to grant clearance. The formal rejection was directly tied to the performance of the therapeutic in clinical testing. Specifically, the drug's clinical trial failed to achieve its primary survival benchmark, preventing it from securing regulatory clearance.
Key points
- Summit's experimental lung cancer medication was not granted approval by the U.S. regulat…: Summit's experimental lung cancer medication was not granted approval by the U.S. regulatory agency.
- The regulatory rejection was triggered directly by the clinical trial's failure to meet k…: The regulatory rejection was triggered directly by the clinical trial's failure to meet key survival goals.
- Missing the main primary survival target has halted the market progression of this therap…: Missing the main primary survival target has halted the market progression of this therapeutic candidate.